Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer

Pathology Research and Practice

Volumn 209, Issue 6, 2013, Pages 365-370

  Noh, Sang Jae ^a   Baek, Hyun Ah ^a   Park, Ho Sung ^a   Jang, Kyu Yun ^a   Moon, Woo Sung ^a   Kang, Myoung Jae ^a   Lee, Dong Geun ^a   Kim, Min Ho ^a   Lee, Ju Hyung ^a   Chung, Myoung Ja ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Carcinoma; Cortactin; Non small cell lung; SIRT1

Indexed keywords

CORTACTIN; SIRTUIN 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ADENOCARCINOMA IN SITU; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR INVASION;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA IN SITU; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CORTACTIN; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SIRTUIN 1; TIME FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84878413968     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.03.011     Document Type: Article

References (33)

1. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
2. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 2000, 14:1021-1026.
3. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L., Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., Greenberg M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
4. Chen W.Y., Wang D.H., Yen R.C., Luo J., Gu W., Baylin S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123:437-448.
5. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., Pelicci P.G., Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002, 21:2383-2396.
6. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
7. Motta M.C., Divecha N., Lemieux M., Kamel C., Chen D., Gu W., Bultsma Y., McBurney M., Guarente L. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004, 116:551-563.
8. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
9. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., Mayo M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23:2369-2380.
10. Tang B.L. Sirt1 and cell migration. Cell Adhes. Migr. 2010, 4:163-165.
11. Rodrigo J.P., Garcia-Carracedo D., Garcia L.A., Menendez S., Allonca E., Gonzalez M.V., Fresno M.F., Suarez C., Garcia-Pedrero J.M. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol. 2009, 217:516-523.
12. Rodrigo J.P., Garcia L.A., Ramos S., Lazo P.S., Suarez C. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. 2000, 6:3177-3182.
13. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene 1995, 159:83-96.
14. Hui R., Ball J.R., Macmillan R.D., Kenny F.S., Prall O.W., Campbell D.H., Cornish A.L., McClelland R.A., Daly R.J., Forbes J.F., Blamey R.W., Musgrove E.A., Robertson J.F., Nicholson R.I., Sutherland R.L. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 1998, 17:1053-1059.
15. Luo M.L., Shen X.M., Zhang Y., Wei F., Xu X., Cai Y., Zhang X., Sun Y.T., Zhan Q.M., Wu M., Wang M.R. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res. 2006, 66:11690-11699.
16. Myllykangas S., Bohling T., Knuutila S. Specificity, selection and significance of gene amplifications in cancer. Semin. Cancer Biol. 2007, 17:42-55.
17. Yuan B.Z., Zhou X., Zimonjic D.B., Durkin M.E., Popescu N.C. Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma. J. Mol. Diagn. 2003, 5:48-53.
18. Zhang L., Liu T., Huang Y., Liu J. microRNA-182 inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on human cortical actin-associated protein. Int. J. Mol. Med. 2011, 28:381-388.
19. Weaver A.M. Cortactin in tumor invasiveness. Cancer Lett. 2008, 265:157-166.
20. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L.A.T. American Joint Committee on Cancer, Cancer Staging Manual 2009, Springer, New York. 7th ed.
21. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart 2004, IARC Press, Lyon.
22. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., Beer D.G., Powell C.A., Riely G.J., Van Schil P.E., Garg K., Austin J.H., Asamura H., Rusch V.W., Hirsch F.R., Scagliotti G., Mitsudomi T., Huber R.M., Ishikawa Y., Jett J., Sanchez-Cespedes M., Sculier J.P., Takahashi T., Tsuboi M., Vansteenkiste J., Wistuba I., Yang P.C., Aberle D., Brambilla C., Flieder D., Franklin W., Gazdar A., Gould M., Hasleton P., Henderson D., Johnson B., Johnson D., Kerr K., Kuriyama K., Lee J.S., Miller V.A., Petersen I., Roggli V., Rosell R., Saijo N., Thunnissen E., Tsao M., Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011, 6:244-285.
23. Cha E.J., Noh S.J., Kwon K.S., Kim C.Y., Park B.H., Park H.S., Lee H., Chung M.J., Kang M.J., Lee D.G., Moon W.S., Jang K.Y. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer Res. 2009, 15:4453-4459.
24. You T.K., Kim K.M., Noh S.J., Bae J.S., Jang K.Y., Chung M.J., Moon W.S., Kang M.J., Lee D.G., Park H.S. Expressions of E-cadherin, cortactin and MMP-9 in pseudoepitheliomatous hyperplasia and squamous cell carcinoma of the head and neck: their relationships with clinicopathologic factors and prognostic implication. Korean J. Pathol. 2012, 46:331-340.
25. Jang K.Y., Hwang S.H., Kwon K.S., Kim K.R., Choi H.N., Lee N.R., Kwak J.Y., Park B.H., Park H.S., Chung M.J., Kang M.J., Lee D.G., Kim H.S., Shim H., Moon W.S. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2008, 32:1523-1531.
26. Jang K.Y., Kim K.S., Hwang S.H., Kwon K.S., Kim K.R., Park H.S., Park B.H., Chung M.J., Kang M.J., Lee D.G., Moon W.S. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009, 41:366-371.
27. Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M., Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P., Reinberg D. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1859-1864.
28. Tseng R.C., Lee C.C., Hsu H.S., Tzao C., Wang Y.C. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia 2009, 11:763-770.
29. Yamazaki D., Kurisu S., Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005, 96:379-386.
30. Wong S., Weber J.D. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem. J. 2007, 407:451-460.
31. Zhang Y., Zhang M., Dong H., Yong S., Li X., Olashaw N., Kruk P.A., Cheng J.Q., Bai W., Chen J., Nicosia S.V., Zhang X. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2009, 28:445-460.
32. Jin Q., Yan T., Ge X., Sun C., Shi X., Zhai Q. Cytoplasm-localized SIRT1 enhances apoptosis. J. Cell. Physiol. 2007, 213:88-97.
33. Byles V., Chmilewski L.K., Wang J., Zhu L., Forman L.W., Faller D.V., Dai Y. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int. J. Biol. Sci. 2010, 6:599-612.